title: Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment.
abstract: BACKGROUND
  Dendritic and histiocytic cell neoplasms are rare malignancies that make up less than 1% of all neoplasms arising in lymph nodes or soft tissues. These disorders have distinctive disease biology, clinical presentations, pathology, and unique treatment options. Morphology and immunohistochemistry evaluation by a hematopathologist remains key for differentiating between these neoplasms. In this review, we describe tumor biology, clinical features, pathology, and treatment of follicular dendritic cell sarcoma, interdigitating dendritic cell sarcoma, indeterminate dendritic cell sarcoma, histiocytic sarcoma, fibroblastic reticular cell tumors, and disseminated juvenile xanthogranuloma.
  
  
  METHODS
  A literature search for articles published between 1990 and 2013 was undertaken. Articles are reviewed and salient findings are systematically described.
  
  
  RESULTS
  Patients with dendritic cell and histiocytic neoplasms have distinct but variable clinical presentations; however, because many tumors have recently been recognized, their true incidence is uncertain. Although the clinical features can present in many organs, most occur in the lymph nodes or skin. Most cases are unifocal and solitary presentations have good prognoses with surgical resection. The role of adjuvant therapy in these disorders remains unclear. In cases with disseminated disease, prognosis is poor and data on treatment options are limited, although chemotherapy and referral to a tertiary care center should be considered. Excisional biopsy is the preferred method of specimen collection for tissue diagnosis, and immunohistochemistry is the most important diagnostic method for differentiating these disorders from other entities.
  
  
  CONCLUSIONS
  Dendritic cell and histiocytic cell neoplasms are rare hematological disorders with variable clinical presentations and prognoses. Immunohistochemistry remains important for diagnosis. Larger pooled analyses or clinical trials are needed to better understand optimal treatment options in these rare disorders. Whenever possible, patients should be referred to a tertiary care center for disease management.
authors.affiliation: Mercy Clinic Oncology-Hematology, Joplin, MO 64804, USA. sdalia@gmail.com.
authors.forename: Samir
authors.initials: S
authors.lastname: Dalia
authors.forename: Haipeng
authors.initials: H
authors.lastname: Shao
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Sagatys
authors.forename: Hernani
authors.initials: H
authors.lastname: Cualing
authors.forename: Lubomir
authors.initials: L
authors.lastname: Sokol
mesh_terms: D003713:Dendritic Cells / Q000473:pathology*; D019337:Hematologic Neoplasms; D015620:Histiocytic Disorders, Malignant; D006801:Humans